



04-08-02

0430

#2

C-2916/4 (PHA 4151.7)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Susan A. Gregory et al.

Serial No. 10/098,644

Filed March 15, 2002

For IMMUNOSUPPRESSIVE EFFECTS OF ADMINISTRATION OF A
CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR

April 5, 2002

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS,

SIR:

INFORMATION DISCLOSURE STATEMENT


In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit copies of the references listed on the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.

Respectfully submitted,

Kathryn J. Doty, Reg. No.
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

PKF/mkd

Express Mail Label No. EL937979483US



PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/098,644
				Filing Date	March 15, 2002
				First Named Inventor	Susan A. Gregory
Sheet	1	of	2	Attorney Docket No.	C-2916/4 (PHA 4151.7)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	1	4,686,231		Bender et al.	08-11-1987
	2	4,889,935		Musser	12-26-1989
	3	5,272,178		Mueller et al.	12-21-1993
	4	5,403,857		Edwards et al.	04-04-1995

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
	5	DET WO	WO 96/38418		Talley et al.	12-05-1996	
	6	DET WO	WO 96/38442		Rogers	12-05-1996	
	7	DET WO	WO 97/29776		Gregory et al.	08-21-1997	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number

10/098,644

Filing Date

March 15, 2002

First Named Inventor

Susan A. Gregory

Sheet

2

of

2

Attorney Docket No.

C-2916/4 (PHA 4151.7)

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	8	CARTER et al., 5-Lipoxygenase Inhibitory Activity of Zileuton ¹ , <i>J. Pharm. and Exp. Ther.</i> , 1991, pp. 929-37, Vol. 256, No. 3, American Society for Pharmacology and Experimental Therapeutics, 1991	
	9	CHANG et al., Prevention of ocular inflammation by matriline, prednisolone, and cyclooxygenase and lipoxygenase inhibitors, <i>Acta Pharmacologica Sinica</i> , March 1991, pp. 121-25, Vol. 12, No. 2	
	10	RUBIN et al., Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase, <i>Prog. in Inflam. Res. and Therapy</i> , 1991, pp. 103-16	
	11	TENNANT et al., Effects of a 5-lipoxygenase inhibitor, REV-5901, on leukotriene and histamine release from human lung tissue in-vitro, <i>J. Pharmacy and Pharmacology</i> , April 1987, pp. 309-11, Vol. 39, No. 4	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.